BridgeBio Pharma (BBIO) holder files to sell 13,600 shares under Rule 144

Rhea-AI Filing Summary

A holder of BridgeBio Pharma (BBIO) has filed a notice of proposed sale under Rule 144 covering 13,600 shares of common stock. The filing lists an aggregate market value of $1,016,147.12 for these shares, with 192,708,813 shares outstanding at the issuer. The shares were acquired as restricted stock from the issuer on 02/16/2025 and are expected to be sold around 02/17/2026 through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	13600	1016147.12	192708813	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/16/2025	Restricted Stock	ISSUER			13600	02/16/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the BBIO Form 144 filing disclose?

The Form 144 discloses a planned sale of 13,600 BridgeBio Pharma common shares. The seller intends to rely on Rule 144 to sell these restricted shares into the market, documenting share amount, value, acquisition details, and sale method.

How many BridgeBio Pharma (BBIO) shares are planned for sale?

The filing shows a planned sale of 13,600 shares of BridgeBio Pharma common stock. This figure reflects the specific block the holder seeks to sell under Rule 144 and is separate from the company’s total shares outstanding.

What is the aggregate market value of the BBIO shares in this Form 144?

The aggregate market value of the 13,600 BridgeBio Pharma shares covered by the notice is $1,016,147.12. This value helps investors gauge the approximate size of the proposed secondary sale relative to typical daily trading activity.

When were the BridgeBio Pharma shares acquired and how?

The 13,600 BridgeBio Pharma shares were acquired on 02/16/2025 as restricted stock from the issuer. Restricted stock generally cannot be freely sold immediately and often requires compliance with Rule 144 resale conditions before entering the public market.

When is the proposed sale date for the BBIO shares under Rule 144?

The notice lists an approximate sale date of 02/17/2026 for the 13,600 shares. This indicates when the holder expects to begin selling the restricted stock into the market, subject to Rule 144 conditions and broker execution.

Through which broker and exchange will the BBIO shares be sold?

The planned sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ exchange. Naming the broker and exchange clarifies how the shares may enter the public market under this Rule 144 transaction.

How many BridgeBio Pharma shares are outstanding in this Form 144?

The filing reports 192,708,813 BridgeBio Pharma shares outstanding. This provides a baseline for understanding the relative size of the 13,600-share planned sale compared with the company’s overall equity base at the time of the notice.